Home / Drug shortages / Neostigmine Methylsulfate Injection

Neostigmine Methylsulfate Injection — FDA Drug Shortage

To Be Discontinued — Fresenius Kabi USA, LLC

The FDA lists a drug shortage record for Neostigmine Methylsulfate Injection (injection) from Fresenius Kabi USA, LLC with status To Be Discontinued. The shortage was first posted on 01/12/2026.

Shortage Details

Status
To Be Discontinued
Company
Fresenius Kabi USA, LLC
Package NDC
63323-413-10
Dosage Form
Injection
Presentation
Neostigmine Methylsulfate, Injection, .5 mg/1 mL (NDC 63323-413-10)
Initial Posting
01/12/2026
Revised Date

FDA data resources